Blar i NTNU Open på forfatter "Tholin, Birgitte"

Viser treff 1-3 av 3

    • Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial 

      Barratt-Due, Andreas; Olsen, Inge Christoffer; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Lund-Johansen, Fridtjof; Hoel, Hedda Benedicte; Holten, Aleksander Rygh; Tveita, Anders Aune; Mathiessen, Alexander; Haugli, Mette; Eiken, Ragnhild; Kildal, Anders Benjamin; Berg, Åse; Johannessen, Asgeir; Heggelund, Lars; Dahl, Tuva Børresdatter; Skåra, Karoline Hansen; Pawel, Mielnik; Le, Lan Ai Kieu; Thoresen, Lars; Ernst, Gernot; Hoff, Dag Arne Lihaug; Skudal, Hilde Kristin; Kittang, Bård Reiakvam; Olsen, Roy Bjørkholt; Tholin, Birgitte; Ystrøm, Carl Magnus; Skei, Nina Vibeche; Tran, Trung; Dudman, Susanne Gjeruldsen; Andersen, Jan Terje; Hannula, Raisa; Dalgard, Olav; Finbråten, Ane-Kristine; Tonby, Kristian; Blomberg, Bjørn; Aballi, Saad; Fladeby, Cathrine; Steffensen, Anne Katrine; Müller, Fredrik; Dyrhol-Riise, Anne Ma; Trøseid, Marius; Aukrust, Pål (Peer reviewed; Journal article, 2021)
      Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the ...

    • Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis 

      Tholin, Birgitte; Ghanima, Waleed Khalid; Einvik, Gunnar; Aarli, Bernt Bøgvald; Brønstad, Eivind; Skjønsberg, Ole Henning; Stavem, Knut (Peer reviewed; Journal article, 2021)
      Infection with coronavirus disease-2019 (COVID-19) may predispose for venous thromboembolism (VTE). There is wide variation in reported incidence rates of VTE in COVID-19, ranging from 3% to 85%. Therefore, the true incidence ...

    • Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses 

      Pan, Hongchao; Peto, Richard; Karim, Quarraisha Abdool; Alejandria, Marissa M.; Henao-Restrepo, Ana-Maria; Hernández-García, César; Kieny, Marie-Paule; Malekzadeh, Reza; Murthy, Srinivas; Preziosi, Marie-Pierre; Reddy, K Srinath; Periago, Mirta Roses; Sathiyamoorthy, Vasee; Røttingen, John-Arne; Swaminathan, Soumya; Ryan, Michael; Maggioni, Aldo; Babiker, Abdel; Cook, Deborah; Dondorp, Arjen; Kang, Gagandeep; Aukrust, Pål; Barratt-Due, Andreas; Dalgard, Olav; Vinge, Leif Erik; Kittang, Bård Reiakvam; Blomberg, Bjørn; Ystrøm, Carl Magnus; Eiken, Ragnhild; Skei, Nina Vibeche; Hoel, Hedda; Tholin, Birgitte; Hoff, Dag Arne Lihaug; Dyrhol-Riise, Anne Ma; Holten, Aleksander Rygh; Kåsine, Trine; Nezvalova-Henriksen, Katerina; Olsen, Inge Christoffer; Trøseid, Marius; Aballi, Saad; Bjørkholt Olsen, Roy; Haugli, Mette; Berg, Åse; Skudal, Hilde Kristin; Hannula, Raisa; Kildal, Anders Benjamin; Johannessen, Asgeir; Tveita, Anders Aune; Heggelund, Lars; Ernst, Gernot Walter; Thoresen, Lars (Peer reviewed; Journal article, 2022)
      Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued ...